Methotrexate
Long-term sarilumab demonstrates no new safety concerns in rheumatoid arthritis
Long-term sarilumab therapy for rheumatoid arthritis demonstrates no new safety outcomes regardless of concurrent use of conventional synthetic disease-modifying antirheumatic drugs, according to data published in Rheumatology.
Methotrexate plus pegloticase superior to pegloticase alone in gout
Adding methotrexate to pegloticase increased treatment response, compared with pegloticase alone, in patients with uncontrolled gout, according to data published in Arthritis & Rheumatology.
Study raises questions about value of high-dose methotrexate for young patients with ALL
NEW ORLEANS — A shorter initial course of higher-dose dexamethasone failed to reduce toxicity vs. the standard regimen among children and young adults with acute lymphoblastic leukemia and lymphoblastic lymphoma, according to study results.
FDA accepts abbreviated BLA for Biogen’s tocilizumab biosimilar
The FDA has accepted an abbreviated biologics license application for a tocilizumab biosimilar candidate, according to a press release from Biogen.
Switching from adalimumab to upadacitinib demonstrates clinical improvement for patients with RA
PHILADELPHIA — An early switch from adalimumab to upadacitinib due to non-response demonstrated clinical improvement among patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.
'Strange times’: Prescribing methotrexate legally ‘low risk’ Post-Roe
PHILADELPHIA — Rheumatologists are unlikely to be held liable under a state’s anti-abortion laws for prescribing methotrexate for a rheumatic disease, according to a law professor who spoke at ACR Convergence 2022.
One-week methotrexate hold as effective as two-week hold after flu vaccine for RA patients
PHILADELPHIA — Discontinuing methotrexate for 1 week after influenza vaccination offers similar seroprotection as pausing for 2 weeks in patients with rheumatoid arthritis, according to data presented at ACR Convergence 2022.
Severe infection risk for lupus lower with belimumab vs. oral immunosuppressants
PHILADELPHIA — Patients with non-renal systemic lupus erythematosus who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.
ACR outgoing president: Rheumatologists must balance ‘activism’ with focus on care
PHILADELPHIA — The “lanes” of medical organizations such as the American College of Rheumatology are widening, as current events require trusted medical professionals to weigh in, said outgoing ACR president Kenneth G. Saag, MD, MSc.
VIDEO: Pegloticase, methotrexate treats uncontrolled gout without compromising kidney
ORLANDO — In this video from ASN Kidney Week, Abdul A. Abdellatif, MD, discusses the efficacy of pegloticase treatment in conjunction with methotrexate for patients with uncontrolled gout.